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portive care did not improve clinical outcomes in high-risk 
IgAN patients. A Syk-targeted approach may be beneficial 
and is currently being evaluated in a phase II randomized 
controlled trial. In this review, we will discuss the pathogen-
ic role of Syk and potential use of Syk inhibitor in a variety of 
renal diseases.  © 2016 The Author(s) 
Published by S. Karger AG, Basel 
 Introduction 
 Protein tyrosine kinases (PTKs) play a crucial role in 
the regulation of cellular growth and transformation by 
catalyzing the transfer of γ-phosphate of ATP to the hy-
droxyl group of tyrosine in a protein substrate  [1] . There 
are 2 classes of PTKs in cells, including the transmem-
brane receptor PTKs and non-receptor PTKs. Receptor 
PTKs typically have an extracellular domain responsible 
for binding of ligands, a transmembrane domain for an-
chorage and an intracellular domain for signal transduc-
tion  [2] . After binding of a ligand to a receptor PTK, it 
triggers dimerization and autophosphorylation of the 
receptor, followed by activation of downstream signal-
ing pathways  [2] . Non-receptor PTKs are subdivided 
into 9 main families. They interact with receptor PTKs 
and are involved in signaling pathways which regulate 
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 Abstract 
 Spleen tyrosine kinase (Syk), a 72 kDa cytoplasmic non-re-
ceptor protein-tyrosine kinase, plays an important role in 
signal transduction in a variety of cell types. Ever since its 
discovery in the early 1990s, there has been accumulating 
evidence to suggest a pathogenic role of Syk in various al-
lergic disorders, autoimmune diseases and malignancies. 
Additionally, there is emerging data from both pre-clinical 
and clinical studies that Syk is implicated in the pathogenesis 
of proliferative glomerulonephritis (GN), including anti-glo-
merular basement membrane disease, anti-neutrophil cyto-
plasmic antibody-associated GN, lupus nephritis and immu-
noglobulin A nephropathy (IgAN). Moreover, recent animal 
studies have shed light on the importance of Syk in mediat-
ing acute renal allograft rejection, Epstein Barr virus-associ-
ated post-transplant lymphoproliferative disease and kid-
ney fibrosis. Fostamatinib, an oral Syk inhibitor, has under-
gone clinical testing in rheumatoid arthritis, refractory 
immune thrombocytopenic purpura, leukemia and lympho-
ma. The recent STOP-IgAN trial showed that the addition of 
non-selective immunosuppressive therapy to intensive sup-
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cellular migration, proliferative, differentiation and sur-
vival  [3] .
 In 1990, Kobayashi et al. [4] purified a 40 kDa cyto-
solic PTK which had autophosphorylation activity from 
porcine spleen. In 1991, Taniguchi et al. [5] showed that 
this 40 kDa kinase was a proteolytic breakdown product 
of a 72 kDa non-receptor PTK and cloned the spleen ty-
rosine kinase (Syk) gene. In 1994, the Syk gene was 
mapped to chromosome 9q22 in humans  [6] . The Syk 
protein (629 amino acids) contains a pair of Src homol-
ogy 2 (SH2) domains at the N-terminus and a carboxy‐
terminal tyrosine kinase domain  [7] . These domains are 
linked by 2 linker regions: interdomain A between the 
2 SH2 domains and interdomain B between the C‐ter-
minal SH2 domain and the kinase domain. In inactive 
form, Syk assumes a closed, autoinhibited structure 
where the aromatic residues in interdomain A, interdo-
main B and the kinase domain interact to form a ‘linker-
kinase sandwich’  [7] . Activation of Syk occurs via en-
gagement of the SH2 domains or phosphorylation of ty-
rosine residues involved in the ‘linker-kinase sandwich’. 
Syk activation results in a conformational change that 
allows the exposed catalytic kinase domain to interact 
with downstream targets  [7] . Syk is widely expressed in 
hematopoietic cells and involved in coupling activated 
immunoreceptors to downstream signaling events that 
mediate cellular proliferation, differentiation and 
phagocytosis  [8] . The schematic structure, general 
mechanism of Syk activation, receptors involved and 
cellular responses in different cell types after activation 
of Syk is summarized in  figure 1 . The role of Syk in var-
ious biological functions has been comprehensively re-
viewed elsewhere  [8] .
 Ever since its discovery, there has been accumulating 
evidence to suggest a pathogenic role of Syk in various al-
lergic disorders, autoimmune diseases  [9] and malignan-
cies  [10] . There is also emerging data from both pre-clin-
ical and clinical studies that Syk is implicated in the 
pathogenesis of various renal disorders, including prolif-
erative glomerulonephritis (GN), acute renal allograft re-
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 Fig. 1. Summary of the schematic structure, general mechanism 
of Syk activation, receptors involved and cellular responses in dif-
ferent cell types after activation of Syk. Recruitment of Syk to plas-
ma membrane receptors occurs through binding of the SH2 do-
mains of Syk to 2 phosphorylated tyrosine residues (P) in the im-
munoreceptor tyrosine-based activation motif (ITAM) present in 
the receptor-associated transmembrane adaptor. Recruitment of 
Syk to dually phosphorylated ITAM triggers the activation of Syk 
and activates downstream signal transduction, which eventually 
triggers various cellular responses. Classical immunoreceptors re-
fer to those signaling molecules that are directly coupled to ITAM 
adapters FcRγ or DAP12 through transmembrane charged resi-
dues. These immunoreceptors consist of immunoglobulin super-
family-containing proteins (such as the Fc receptors, PIR-A or the 
TREMs) or the C-type lectin receptors (Dectin-2, Mincle, or 
MDL-1). 
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jection, Epstein Barr virus (EBV)-associated post-trans-
plant lymphoproliferative disease (PTLD) and kidney fi-
brosis. Given the role of Syk in a wide range of diseases, 
various small molecular Syk inhibitors are being devel-
oped  [11] . Fostamatinib is an oral Syk inhibitor that has 
been tested in clinical trials on patients with rheumatoid 
arthritis (RA), refractory immune thrombocytopenic 
purpura, leukemia and lymphoma  [12, 13] . There is an 
ongoing phase II randomized controlled trial to assess the 
safety and efficacy of fostamatinib in immunoglobulin A 
nephropathy (IgAN). In this review, we will discuss the 
pathogenic role of Syk and potential use of Syk inhibitor 
in different renal diseases.
 Pathogenic Role of Syk in Renal Disease (Table 1) 
 Glomerulonephritis 
 GN is an important cause of acute kidney injury (AKI) 
and chronic kidney disease. Rapidly progressive GN 
(RPGN), or crescentic GN, is an aggressive disease. Anti-
glomerular basement membrane (anti-GBM) disease and 
anti-neutrophil cytoplasmic antibody (ANCA)-associat-
ed GN (AAGN) are important causes of RPGN, and Syk 
has been shown to play a crucial role in both conditions. 
Syk has also been implicated in the pathogenesis of im-
mune complex-mediated GN, including lupus nephritis 
(LN) and IgAN.
Table 1.  Summary of intervention studies of Syk inhibitor in animal models
Animal model, reference Resemblance of 
human disease
Intervention Salient findings
EAG [16] Anti-GBM disease Syk inhibitor (R788) Prevention of EAG (given before immunization)
Reduced GN severity and prevention of pulmonary 
hemorrhage (given after established disease)
NTN [17, 18] Anti-GBM disease Syk inhibitor (R788)
Conditional Syk gene 
deletion in myeloid cells
Reduced GN severity when treatment started after 
established disease
Reduced GN severity
EAV [24] ANCA-associated 
vasculitis/AAGN
Syk inhibitor (R788) Reduced GN severity and pulmonary hemorrhage
Lupus prone NZB/NZW 
mice [31]
SLE and LN Syk inhibitor (R788) Delayed onset and reduced GN severity (given 
before disease onset)
Reduced GN severity (given after disease onset)
MRL/lpr and BAK/BAX 
double-knockout mice [32]
SLE and skin disease Syk inhibitor (R788) Delayed onset and reduced severity of skin disease 
(given before disease onset) Reduced severity of 
skin disease (given after disease onset)
MRL/lpr mice [32] SLE and lupus nephritis Syk inhibitor (R788) Prevention of GN (given before immunization)
Reduced GN severity (given after established 
disease)
Experimental acute renal 
allograft rejection 
(Brown Norway to Lewis) 
[35, 36]
Acute renal 
allograft rejection
Syk inhibitor (R788) Prevention of allograft infarction and reduced 
interstitial infiltrates
Decreased donor-specific antibody
Experimental acute renal 
allograft rejection 
(Wistar to Dawley) [37]
Acute renal allograft 
rejection
Syk inhibitor (CC0482417) Improved allograft function, reduced infiltration of 
macrophages and neutrophils, attenuated acute 
tubular injury and peritubular capillary thrombosis
UUO [41] Renal fibrosis Syk inhibitor (CC0417) Reduced macrophage infiltration
NTN [40] Renal fibrosis Syk inhibitor (R788) Late treatment (days 14–28) using Syk inhibitor 
reduced deposition of interstitial collagen, 
glomerular expression of α-smooth muscle actin 
and glomerular synthesis of transforming growth 
factor-β Reduced renal fibrosis
Improved renal function
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 Anti-GBM Disease 
 Experimental autoimmune GN (EAG) and nephro-
toxic nephritis (NTN) are 2 widely used animal models 
that resemble human anti-GBM disease. In EAG, ani-
mals are immunized with heterologous or homologous 
GBM or NC1 domain of the α-3 chain of type IV colla-
gen. Immunized animals subsequently mount an auto-
immune response and develop anti-GBM antibodies 
that attack their own kidneys  [14] . On the contrary, 
there are 2 phases of injury in NTN. In the heterologous 
phase, animals are injected with a heterologous anti-
GBM antibody, which deposits in the kidney and causes 
transient injury. In the autologous phase, the foreign an-
tibody acts as a planted antigen on the GBM which trig-
gers an autoimmune response in the animal  [15] . Al-
though these models have been developed in various 
species, the most consistent model is that induced in 
Wistar-Kyoto (WKY) rats. Immunohistochemistry 
(IHC) study has demonstrated increased glomerular to-
tal Syk (T-Syk) and phosphorylated Syk (P-Syk) expres-
sion in EAG  [16] . T-Syk includes both phosphorylated 
(active) and unphosphorylated (inactive) forms of Syk. 
Syk plays a crucial role in the activation of stress-activat-
ed protein kinases like c-Jun N-terminal kinase and p38 
mitogen-activated protein kinase, which are responsible 
for leukocyte-mediated renal injury  [17, 18] . When 
NTN was induced in mice with conditional Syk gene de-
letion in myeloid cells, there were significantly less leu-
kocytic infiltration, crescent formation, inflammation 
and fibrosis when compared with controls  [19] . Admin-
istration of fostamatinib (R788), an oral prodrug of the 
selective Syk inhibitor tamatinib (R406), completely 
prevented the induction of EAG when it was given 1 h 
before immunization. When given from day 18 to 36 af-
ter induction of EAG, fostamatinib led to cessation of 
autoantibody production, reversal of renal injury, pres-
ervation of renal function and complete protection from 
pulmonary hemorrhage  [16] . Additionally, fostama-
tinib inhibited production of proinflammatory cyto-
kines by nephritic glomeruli ex vivo and cultured bone 
marrow-derived macrophages in vitro, suggesting ad-
ditional therapeutic effects related to inhibited Fc recep-
tor signaling within macrophages in diseased glomeruli 
which were independent of suppression of autoantibody 
production  [16] . Similar beneficial effects of fostama-
tinib have also been observed in NTN models  [18, 20] . 
In human anti-GBM disease, previous IHC study 
showed increased glomerular T-Syk and P-Syk expres-
sion  [21] . Syk appeared to localize to infiltrating macro-
phages and neutrophils. A strong correlation between 
glomerular T-Syk expression and serum creatinine at 
presentation was observed ( fig. 2 a). Dialysis-dependent 
patients had significantly higher levels of glomerular T-
Syk expression  [21] .
 ANCA-Associated GN 
 ANCA-associated vasculitis and AAGN are character-
ized by the presence of antibodies directed against pro-
teinase-3 or myeloperoxidase (MPO). In vitro study 
showed that ANCA-IgG induced phosphorylation of Syk 
in tumor necrosis factor-primed neutrophils from healthy 
donors  [22] . Piceatannol (a Syk inhibitor) inhibited Syk 
phosphorylation as well as ANCA-stimulated respiratory 
burst  [22] . Several animal models have been developed to 
demonstrate the pathogenicity of ANCA in vivo, as re-
cently summarized elsewhere  [23] . In experimental auto-
immune vasculitis, where WKY rats are immunized with 
MPO, renal disease can be induced after 4 weeks  [23] . 
Fostamatinib, given for established renal disease, signifi-
cantly reduced hematuria, proteinuria, macrophage infil-
tration and pulmonary hemorrhage  [24] . In patients with 
AAGN, glomerular T-Syk expression was upregulated 
and correlated with serum creatinine at the time of bi-
opsy as well as the histological class of disease  [21] . Four 
histopathological classes of lesions have been proposed 
for prognostication of AAGN patients, namely focal, 
crescentic, mixed and sclerotic  [25] . T-Syk staining was 
highest in patients with crescentic (acute) disease but 
minimal in sclerotic (chronic) disease ( fig. 2 b)  [21] .
 Lupus Nephritis 
 Systemic lupus erythematosus (SLE) is a complex, 
multi-system, autoimmune disease characterized by ab-
normalities in both T and B cells  [26] . Compared with 
normal T cells, T cells obtained from SLE patients dem-
onstrated substantially higher Syk expression and activ-
ity  [27] . In vitro study showed that Syk was responsible 
for upregulation of various cytokines, receptors and en-
zymes involved in the immunopathogenesis of SLE, in-
cluding CD44 (involved in T cell migration), interleukin 
(IL)-21 (involved in antibody production), OAS2 
(2’-5’-oligoadenylate synthetase; involved in type I inter-
feron response) and protein phosphatase 2A (involved in 
regulation of IL-2 production)  [28] . The cardinal abnor-
malities of B cells in SLE include loss of B cell tolerance 
resulting in autoantibody production and hyperactive B 
cell receptor (BCR)-triggered signaling  [29] . Murine 
models of SLE and LN are widely used and considered to 
be the best tool to study human SLE  [30] . Fostamatinib, 
no matter given before or after disease onset, delayed the 
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onset of proteinuria and azotemia, reduced renal pathol-
ogy and kidney infiltrates and significantly prolonged 
survival in lupus prone NZB/NZW mice  [31] . In MRL/
lpr and BAK/BAX double-knockout mice, fostamatinib 
prevented development of skin disease when given be-
fore disease onset and significantly reduced severity of 
skin disease when given after disease onset  [32] . In MRL/
lpr mice, fostamatinib could prevent the development of 
renal disease and reduce proteinuria in established dis-
ease  [32] . In LN patients, those with class IV (diffuse pro-
liferative) LN had the highest T-Syk and P-Syk expres-
sions  [21] . Minimal T-Syk staining was seen in class V 
disease ( fig. 2 c). There was also a trend of higher T-Syk 
expression in patients who failed to achieve complete re-
mission (CR) by 6 months compared with patients who 
achieved CR. However, there was no association between 
T-Syk expression and serum creatinine or proteinuria 
 [21] .
 IgA Nephropathy 
 IgAN is the most common primary GN worldwide. A 
multi-hit pathogenesis model has been proposed  [33] . 
Initially, there is increased production of galactose-defi-
cient IgA1 (hit 1), followed by formation of autoantibod-
ies directed against galactose-deficient IgA1 (hit 2). These 
autoantibodies subsequently bind with galactose-defi-
cient IgA1 to form pathogenic immune complexes (hit 3), 
which deposit in the mesangium, activate mesangial cells 
and induce glomerular injury (hit 4). Previous in vitro 
study demonstrated that Syk was involved in activation of 
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 Fig. 2. Correlation between Syk expression and disease activity in 
proliferative GN (reproduced with permission from [21].  a Cor-
relation between T-Syk expression and serum creatinine in human 
anti-GBM disease.  b Correlation between T-Syk expression and 
histopathological classes in human AAGN.  c Correlation between 
T-Syk expression and histopathological classes in human LN.  d 
Correlation between T-Syk expression and Oxford classification 
scores in human IgA nephropathy.  * * p < 0.01;  * * * * p < 0.0001. E = 
Endocapillary proliferation; GCS = glomerular cross section; M = 
mesangial hypercellularity. 
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mesangial cell proliferation  [34] . Inhibition of Syk by 
pharmacological antagonist (R406) and knockdown of 
Syk by small interfering RNA downregulated synthesis 
and release of a number of proinflammatory mediators 
and platelet-derived growth factor, and reduced cellular 
proliferation in mesangial cells stimulated with IgA1 iso-
lated from IgAN patients  [34] . In IgAN patients, those 
with endocapillary proliferation demonstrated highest 
levels of T-Syk staining, whereas those without prolifera-
tive features or mesangial proliferation only had negligi-
ble staining within the glomerular tuft ( fig. 2 d)  [21] . In 
this study, there was no association between T-Syk ex-
pression and serum creatinine or proteinuria. However, 
a recent study found a significant correlation between the 
number of P-Syk positive glomerular cells and the degree 
of proteinuria and renal function in patients with IgAN, 
further supporting the role of Syk activation in the patho-
genesis of IgAN  [19] .
 Other Renal Diseases 
 In recent years, various animal studies have shed light 
on the pathogenic role of Syk in acute renal allograft ne-
phropathy, EBV-associated PTLD, renal fibrosis and pos-
sibly diabetic nephropathy.
 Acute Renal Allograft Rejection 
 In experimental model of early severe renal allograft 
rejection (Brown Norway to Lewis rats), IHC study 
showed that all rats with acute rejection had Syk-positive 
tubulointerstitial infiltrates  [35] . Increased Syk expres-
sion was also detected in kidney transplant biopsies from 
patients with antibody-mediated rejection or T-cell me-
diated rejection  [35] . Fostamatinib treatment has been 
shown to completely prevent allograft infarction and re-
duce interstitial infiltrates in experimental renal allograft 
rejection  [36] . In another experimental model of renal 
allograft rejection, where Sprague–Dawley rats under-
went bilateral nephrectomy and orthotopic renal trans-
plant from Wistar rats, Ramessur Chandran et al. [37] 
showed dense leukocytic infiltration with strong Syk ex-
pression in the allograft. Administration of Syk inhibitor 
(CC0482417) significantly improved allograft function, 
reduced leukocytic infiltration and attenuated acute tu-
bular injury and peritubular capillary thrombosis  [37] .
 Post-Transplant Lymphoproliferative Disease 
 EBV, a B-cell lymphotropic virus, is associated with a 
wide variety of B cell-derived lymphoid neoplasms, in-
cluding PTLD. The EBV protein latent membrane pro-
tein 2a, which is expressed in the membrane of infected B 
cells, mimics BCR and provides survival signals to EBV-
infected cells through Syk  [38] . In vitro study showed that 
Syk-activated PI3K/Akt signaling was required for the 
survival of EBV-positive B-cell lymphomas and R406 in-
duced apoptosis and cell cycle arrest in EBV-positive 
PTLD cell lines  [39] .
 Renal Fibrosis 
 Renal fibrosis is the hallmark of progressive renal dis-
ease. In WKY rats induced with NTN, fostamatinib treat-
ment from day 14 to 28 (i.e., after established renal disease 
and entering into fibrotic phase) was shown to be effec-
tive in reducing glomerular expression of α-smooth mus-
cle actin (a profibrotic marker) and deposition of inter-
stitial collagen, as well as improving renal function  [40] . 
Ex vivo culture of nephritic glomeruli showed that Syk 
inhibition reduced glomerular synthesis of transforming 
growth factor (a pro-fibrotic cytokine)  [40] .
 The unilateral ureteral obstruction (UUO) model in 
rodents generates progressive renal fibrosis. There is rap-
id and robust induction of renal fibrosis in obstructed 
kidney; hence the day 7 time point is the most commonly 
used end point for analysis of renal fibrosis in the UUO 
model. When UUO mice were treated with a selective Syk 
inhibitor (CC0417) from the time of surgery till day 7, 
there was significantly reduced macrophage infiltration 
( ∼ 50%) compared with vehicle and no treatment groups 
 [41] . It will also be interesting to know if administration 
of Syk inhibitor at a later stage of UUO (e.g., day 14) will 
have the same inhibitory effect on the fibrotic process. It 
should be noted, however, that the effect of Syk inhibition 
on kidney function is difficult to assess in UUO.
 Diabetic Nephropathy 
 Previous in vitro studies showed that Syk was involved 
in high-glucose-induced activation of nuclear factor 
(NF)-κB in human glomerular endothelial cells  [42] and 
proximal tubular cells  [43] . NF-B activation plays an im-
portant role in the signaling pathway of fibrosis. Prelimi-
nary animal study also showed a beneficial role of Syk 
inhibitor in autoimmune diabetes  [44] .
 Syk as a Therapeutic Target 
 A search of the patent literature has revealed more 
than 70 filings describing the development of small mo-
lecular Syk inhibitors  [11] . Fostamatinib is the first clini-
cally available oral Syk inhibitor. After oral administra-
tion, it is rapidly converted to R406 by human intestinal 
D
ow
nl
oa
de
d 
by
: 
Im
pe
ria
l C
ol
le
ge
, S
ch
oo
l o
f M
ed
ici
ne
, W
el
lco
m
e 
Li
br
.  
 
15
5.
19
8.
12
.1
47
 - 
8/
9/
20
16
 3
:5
7:
29
 P
M
 Syk: A Crucial Player and Potential 
Therapeutic Target in Renal Disease 
Nephron
DOI: 10.1159/000446879
7
microsomes, and only low levels of fostamatinib appear 
in the plasma  [45] . Fostamatinib is metabolized primar-
ily by cytochrome P450 3A4  [46] . On an average, fecal 
and urine excretions account for 80 and 19% of drug ex-
cretion, respectively  [45] . The terminal half-life was esti-
mated to be 12–21 h and steady state is achieved after 3–4 
days following twice daily administration. Co-adminis-
tration with food results in delay in peak time and lower 
peak concentrations of R406, but without any change in 
overall exposure. Renal or hepatic impairment did not af-
fect R406 exposure to a clinically relevant extent  [47] . 
Fostamatinib is a P-glycoprotein inhibitor both in vitro 
and in vivo. Reported drug–drug interactions include ke-
toconazole, verapamil, rifampicin  [46] , oral contracep-
tives, simvastatin, rosuvastatin  [48] and digoxin  [49] , but 
not warfarin  [48] . The inhibitory effect of R406 is rela-
tively specific for Syk. Although previous in vitro kinase 
assays showed that R406 did have inhibitory effects on 
other kinases (e.g., Flt3, Lyn, Lck), cell-based assays 
showed that the inhibitor effects were much less potent 
compared with Syk  [50] .
 Fostamatinib has been investigated in multiple phase 
II and phase III clinical trials on RA patients  [51–54] . Hy-
pertension, diarrhea and headache were the most com-
mon adverse effects observed in these trials. The effect of 
fostamatinib on blood pressure elevation (mean increase 
of  ∼ 3 mm Hg in both systolic and diastolic) appeared to 
be dose dependent, and a concentration-dependent in-
crease of blood pressure was observed with increasing 
R406 concentrations. Fostamatinib-induced hyperten-
sion may be attributed to increased vascular resistance, 
secondary to reduced vascular endothelial growth factor-
induced nitric oxide release from endothelium  [55] . 
Blood pressure usually returns to normal upon decrease 
in fostamatinib dose or its withdrawal. Alternatively, ad-
dition or modification of anti-hypertensive drugs can be 
considered.
 The latest KDIGO guidelines suggest that IgAN pa-
tients with persistent proteinuria  ≥ 1 g/day despite 3–6 
months of optimized supportive therapy and estimated 
glomerular filtration rate (eGFR) >50 ml/min/1.73 m 2 to 
receive a 6-month course of corticosteroid therapy  [56] . 
However, this recommendation was recently challenged 
by results of the STOP-IgAN trial  [57] . In this multi-
center, open-label, randomized controlled trial, IgAN pa-
tients with persistent proteinuria  ≥ 0.75 g/day after a 
6-month run-in period of supportive care were random-
ized to receive supportive care alone or supportive care 
plus immunosuppressive therapy for 3 years. In the im-
munosuppression group, patients with eGFR  ≥ 60 ml/
min/1.73 m 2 received glucocorticoid monotherapy for 
6 months, whereas those with eGFR 30–59 ml/min/1.73 m 2 
received cyclophosphamide for 3 months and followed by 
azathioprine, plus a tapering course of steroid. A total of 
80 and 82 patients were randomized to the supportive 
care and immunosuppression group, respectively. After 
3 years, clinical remission (defined as proteinuria with a 
protein-to-creatinine ratio of <0.2 and stable renal func-
tion with a decrease in the eGFR of <5 ml/min/1.73 m 2 ) 
was observed in 5% of the supportive care group, as com-
pared with 17% in the immunosuppression group. How-
ever, there was no significant difference in the annual de-
cline in eGFR between the 2 groups. More importantly, 
more patients in the immunosuppression group had se-
vere infections, impaired glucose tolerance and weight 
gain. Recently, another double-blind, randomized con-
trolled trial comparing mycophenolate mofetil (MMF) 
and placebo was prematurely terminated 6 months after 
it was observed that MMF did not significantly reduce 
proteinuria compared with supportive treatment alone 
 [58] . Results of these recent studies challenged the effi-
cacy and safety of non-selective immunosuppressive 
therapy in IgAN patients. It should be noted that renal 
biopsy data were not reported in these studies. Previous 
study showed that T-Syk expression was observed pre-
dominantly in biopsies with endocapillary proliferation, 
whereas biopsies with no proliferative features or mesan-
gial proliferation only had negligible staining within the 
glomerular tuft  [21] . The use of fostamatinib in IgAN pa-
tients demonstrating proliferative lesions on renal biop-
sies is currently being investigated in a phase II random-
ized controlled trial (NCT02112838). The recruitment 
phase is ongoing and the result is eagerly awaited. A pre-
vious phase II trial on treatment of SLE by Syk inhibitor 
(NCT00752999) was withdrawn prior to enrollment for 
business reasons.
 Conclusion 
 Since its discovery in 1991, there have been more than 
2,000 publications related to Syk. In particular, the last 10 
years have witnessed an intense flowering of interest in 
this unique PTK. Based on the current evidence from 
both pre-clinical and clinical studies, we see a great po-
tential in the development of Syk-targeted therapy for 
treatment of various renal diseases. More studies are re-
quired to delineate the role of Syk in other renal diseases, 
including other types of GN, diabetic nephropathy, tubu-
lointerstitial nephritis and AKI. A clinical trial of fosta-
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matinib in IgAN is ongoing, and future clinical studies on 
the efficacy and safety of fostamatinib for the treatment 
of proliferative and immune complex GN are warranted.
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